SEC Form 4	
------------	--

 \Box

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average bu	rden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

I. Name and Address of Reporting Person* <u>ROBINS HARLAN S</u> (Last) (First) (Middle)					Ad	2. Issuer Name and Ticker or Trading Symbol <u>Adaptive Biotechnologies Corp</u> [ADPT] 3. Date of Earliest Transaction (Month/Day/Year)									v Officer (give title Othe			10% Ov	Owner r (specify	
C/O ADAPTIVE BIOTECHNOLOGIES CORP. SUITE 200							3. Date of Earliest Transaction (Month/Day/Year) 05/14/2020									Chief Scientific Officer				
,		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing Line)											Filing (C	Check Ap	plicable				
(Street) SEATTI	.E V	VA	9	8102												Form filed by One Reporting Person Form filed by More than One Reportin Person				
(City)	(5	State)	(Z	Zip)																
			Table	e I - No	n-Deriv	ative	Se	curiti	ies Ac	quired	, Dis	sposed o	f, or Be	nefi	cially	Owned				
1. Title of Security (Instr. 3)				2. Transa Date (Month/D) E) if	any	med on Date, Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acqu Disposed Of (D) (I		Acquired (A) or D) (Instr. 3, 4 and 5)			Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Direct ndirect r. 4)	7. Nature of Indirect Beneficial Ownership	
										Code	v	Amount	(A) or (D)	Prie	ce	Reported Transaction(s) (Instr. 3 and 4)	tion(s)			(Instr. 4)
Common	Stock				05/14/	2020				M ⁽¹⁾		31,200	A	\$	6.32	101	,879	Γ)	
Common	Stock				05/14/	2020				S ⁽¹⁾		3,200	D	\$ <mark>3</mark>	4.26 ⁽²⁾	98	,679	I)	
Common	Stock				05/14/	2020				S ⁽¹⁾		28,000	D	\$35.44(3)		70,679		I)	
Common	Stock				05/15/	2020				M ⁽¹⁾		35,400) A :		6.32	106	5,079	Ι		
Common	Stock				05/15/2020					S ⁽¹⁾		100	D	\$	33.56	105	105,979)	
Common	Stock				05/15/2020					S ⁽¹⁾		400	D	\$ <mark>3</mark>	5.13 ⁽⁴⁾	105	5,579			
Common	Stock				05/15/2020					S ⁽¹⁾		5,400	D	\$ <mark>3</mark>	6.34 ⁽⁵⁾	100),179	Ι		
Common Stock				05/15/2020					S ⁽¹⁾		22,342	22,342 D \$		37.53 ⁽⁶⁾ 77		,837	Ι			
Common Stock				05/15/2020					S ⁽¹⁾		7,158	D	\$38.11(7)		70	,679	Ι			
Common Stock			05/18/2020					M ⁽¹⁾		11,100	A	\$6.32		81	81,779					
Common Stock			05/18/	2020				S ⁽¹⁾		600	D	\$3	8.67 ⁽⁸⁾	81	,179	Ι)			
Common	Stock				05/18/	2020				S ⁽¹⁾		10,500	D	\$3	9.36 ⁽⁹⁾	70	,679	Ι)	
Common Stock														300),000	Ia	.0)	By CMR 2014 Brother's Trust U/T/A dated July 2, 2014		
Common Stock														500),000	Ια	.0)	By CMR 2014 Mother's Trust U/T/A dated July 2, 2014		
			Ta	able II -								osed of, convertit				Owned				
1. Title of Derivative Security (Instr. 3) 2. Security Price of Derivative Security Derivative			Execution f any	ned 4. n Date, Transa Code (saction e (Instr. berivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Exerci	sable and	7. Title and A of Securities Underlying Derivative Se (Instr. 3 and 4		ount E	B. Price of Derivative Security Instr. 5)		e Ownersl 5 Form: Ily Direct (E or Indire 1 (I) (Instr.	wnership orm:	11. Nature of Indirect Beneficial Ownershi (Instr. 4)		
						Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or	ount nber res					

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		Transaction of Expirat Code (Instr. Derivative (Month			6. Date Exerc Expiration Da (Month/Day/Y				8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$6.32	05/14/2020		M ⁽¹⁾			31,200	(11)	06/09/2025	Common Stock	31,200	\$0.00	480,000	D	
Stock Option (Right to Buy)	\$6.32	05/15/2020		M ⁽¹⁾			35,400	(11)	06/09/2025	Common Stock	35,400	\$0.00	444,600	D	
Stock Option (Right to Buy)	\$6.32	05/18/2020		M ⁽¹⁾			11,100	(11)	06/09/2025	Common Stock	11,100	\$0.00	433,500	D	

Explanation of Responses:

1. These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

2. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$33.91 to 34.90, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the

number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$34.92 to 35.91, inclusive.

4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$34.71 to 35.53, inclusive.

5. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$35.80 to 36.72, inclusive.

6. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$36.98 to 37.97, inclusive.

7. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$37.98 to 38.26, inclusive.

8. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$38.63 to 38.76, inclusive.

9. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$38.91 to 39.89, inclusive.

10. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

11. The option is fully vested and exercisable.

Remarks:

<u>/s/ Harlan Robins by Eric</u> <u>Billings, Attorney-in-Fact</u>

05/18/2020

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.